Group Dynamics and Allocation of Advanced Heart Failure Therapies-Heart Transplants and Ventricular Assist Devices-By

Khadijah Breathett1, Ryan Yee2, Natalie Pool3

  • 1Division of Cardiovascular Medicine Indiana University Indianapolis IN.

Insights

High-quality group decision-making in advanced heart failure therapy (AHFT) allocation benefits women, increasing their likelihood of receiving treatment. Improved group function scores positively impacted women

Area of Science:

  • Cardiology
  • Health Services Research
  • Medical Ethics

Background:

  • US regulatory framework for advanced heart failure therapies (AHFT) relies on center-level multidisciplinary groups for eligibility decisions.
  • Subjective decision-making processes in AHFT allocation are susceptible to racial, ethnic, and gender bias.
  • Understanding the influence of group dynamics on AHFT allocation decisions is crucial for equitable care.

Purpose of the Study:

  • To investigate how group dynamics impact the allocation of advanced heart failure therapies (AHFT) based on patient gender, race, and ethnicity.
  • To assess the relationship between group function scores and AHFT allocation decisions.

Main Methods:

  • A mixed-methods study was conducted across 4 AHFT centers, audio-recording meetings for approximately one month.
  • Meeting transcripts were analyzed using the de Groot Critically Reflective Diagnoses protocol to assess group function (e.g., challenging groupthink, feedback sharing).
  • Hierarchical logistic regression analyzed the association between group function scores and AHFT allocation, adjusting for patient factors and examining interaction effects with gender and race.

Main Results:

  • Among 87 patients evaluated, 57% of women and 38% of men received AHFT.
  • A statistically significant interaction (P=0.035) was found between group function score and patient gender; higher group function scores increased AHFT allocation probability for women and decreased it for men.
  • This gender-based pattern in AHFT allocation associated with group function quality was consistent across racial and ethnic groups.

Conclusions:

  • Women evaluated for advanced heart failure therapies were more likely to be allocated AHFT when group decision-making processes demonstrated higher quality.
  • The findings highlight the potential for improved group decision-making protocols to mitigate disparities in AHFT allocation.
  • Further research is recommended to establish and promote high-quality group decision-making practices to reduce existing disparities in AHFT access.

Related Concept Videos

Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
21
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
19
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
22
Heart Failure IV: Classification and Diagnostic Evaluation01:30

Heart Failure IV: Classification and Diagnostic Evaluation

Heart failure can be classified in various ways, with the most common classifications based on physical activity limitations, disease progression, severity, and treatment strategies.The Functional Classification of Heart Failure divides patients into four categories based on physical activity limitation due to symptom burden.Class I: Patients in this class have cardiac disease but no physical activity limitations. Ordinary activities like walking, climbing stairs, or routine tasks do not cause...
24
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
15
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
479